Keybanc Maintains Overweight on ResMed, Raises Price Target to $238
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Brett Fishbin has maintained an Overweight rating on ResMed (NYSE:RMD) and increased the price target from $227 to $238.
April 26, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keybanc analyst Brett Fishbin has reaffirmed an Overweight rating on ResMed and raised the price target to $238.
The increase in price target by Keybanc suggests a positive outlook on ResMed's stock, likely due to strong performance or favorable market conditions. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100